GEN

New Digital Twin for Recombinant AAV Production

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...
Seeking Alpha

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th ...

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...
GEN

Analytics Key to AV and AAV Manufacturing

Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
Business Wire

VintaBio Unveils New Data Showcasing Scalable AAV Perfusion Manufacturing Platform with High Full Capsid Yield at 2025 ASGCT Annual Meeting

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms

Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...
Business Wire

Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

Virica Biotech will provide a panel of their cell enhancers for use in high-throughput AAV production screening for Ginkgo’s clients. Ginkgo Bioworks will leverage their advanced screening platform ...
The Scientist

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Good Manufacturing Practice (GMP) compliance in adeno-associated virus (AAV)-based cell and gene therapy development can pose significant challenge, including proving capsid ratios to regulators and ...
Nasdaq

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy ...
KOIN 6

Continued Innovation Across Platforms Facilitates Current Pipeline Advancements and Increases Opportunities for Future Pipeline Candidates

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...
Ames Tribune

Diorasis Therapeutics and Northway Biotech Announce Partnership for the Development and Manufacturing of AAV Gene Therapy for Glaucoma

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...
The Manila Times

Viral Vector Manufacturing (VVMF) enters into licensing agreement with OXB, gaining access to the OXB AAV and LV viral vector platforms

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...